Research into the underlying pathogenic mechanisms of acute myeloid leukemia (AML) has
led to remarkable advances in our understanding of the disease. Mutations now allow us to …

Recent advances in acute myeloid leukemia biology and drug development have
transformed the therapeutic landscape for patients diagnosed with this disease. By …

Purpose: To evaluate efficacy and safety of venetoclax+ azacitidine among treatment-naïve
patients with IDH1/2-mutant (mut) acute myeloid leukemia (AML). Patients and Methods …

Background Venetoclax in combination with hypomethylating agents (HMA) is
revolutionizing the therapy of acute myeloid leukemia (AML). However, evidence on large …

Somatic mutations in isocitrate dehydrogenase (IDH) genes occur frequently in adult acute
myeloid leukemia (AML) and less commonly in pediatric AML. The objective of this study …

Simple Summary Chondrosarcomas are cartilage tumours that often harbour a mutation in
one of the isocitrate dehydrogenase (IDH) genes. IDH mutations are important drivers at the …

Mutations of the isocitrate dehydrogenase-1 (IDH1) and IDH2 genes are among the most
frequent alterations in acute myeloid leukemia (AML) and can be found in∼ 20% of patients …

Isocitrate dehydrogenase (IDH) is the key metabolic enzyme that catalyzes the conversion of
isocitrate to α-ketoglutarate (α-KG). Two main types of IDH1 and IDH2 are present in …

Simple Summary Several factors, both patient-and disease-related, are essential to
accurately estimate acute myeloid leukemia (AML) prognosis. The rapidly evolving field …

Background Ferroptosis plays an important role in the development of acute myeloid
leukemia (AML); however, the exact role of ferroptosis-related genes in the prognosis of …